## Content

1. Introduction ·····	·· 1
1.1 Human Vγ9Vδ2 T cells ······	··· 1
1.1.1 Generation of T cell receptor and γδ T cell development ·····	···2
1.1.2 Activation of Vγ9Vδ2 T cells······	5
1.1.2.1 Vγ9Vδ2 TCR repertoire ·····	5
1.1.2.2 TCR-dependent stimulation ·····	6
1.1.2.2.1 PAg generated from the MVA and MEP pathway	6
1.1.2.2.2 Other TCR-dependent activators ·····	9
1.1.2.2.3 The BTN family ·····	9
1.1.2.3 Co-receptors and their ligands	· 14
1.1.2.3.1 Toll-like receptors	• 14
1.1.2.3.2 NK receptors ·····	• 15
1.1.2.3.3 Adhesion molecules ······	• 16
1.1.2.3.4 Fc receptors ·····	· 17
1.1.3 Vγ9Vδ2 T cell immune responses ······	• 18
1.1.3.1 Vγ9Vδ2 T cell immune responses in adults ······	• 18
1.1.3.1.1 Activation, expansion and differentiation	• 18
1.1.3.1.2 Cytotoxicity	• 19
1.1.3.1.3 Secretions	· 20
1.1.3.1.3.1 Cytokines	· 20
1.1.3.1.3.2 Chemokines	· 21
1.1.3.1.3.3 Antimicrobial peptide	· 21
1.1.3.1.4 Interactions with other immune cells	· 22
1.1.3.1.4.1 Monocytes and Dendritic cells	• 22
1.1.3.1.4.2 B cells	· 22
1.1.3.1.4.3 Antigen-presenting to $\alpha\beta$ 1 cells	· 23
1.1.3.2 Vy9Vo2 1 cells immune responses in early life	· 23
1.2 Immune responses to <i>Toxoplasma gondii</i> infection	25
1.2.1 The parasite – <i>Toxoplasma gondii</i> ······	· 25
1.2.2 Basics about toxoplasmosis ·····	· 28
1.2.2.1 Transmission and Prevalence ·····	· 28
1.2.2.2 Symptoms, diagnosis and treatments ·····	· 29
1.2.2.3 Congenital toxoplasmosis ······	· 30
1.2.3 Immune responses to toxoplasmosis ······	• 33
1.2.3.1 Innate immunity to <i>T. gondii</i> infection ······	. 33
1.2.3.2 Adaptive immunity to <i>T. gondii</i> infection ······	· 37
1.2.4 Immune responses to congenital toxoplasmosis ······	• 39
1.2.5 The role of γδ T cells in <i>T. gondii</i> infection ······	· 41
1.3 Immune responses to mistletoe extracts ······	44
1.3.1 Herbal medicine ·····	· 44
1.3.1.1 Herbal medicine – a brief history ·····	· 44
1.3.1.2 Definition of herbal medicine ······	· 46

	1.	3.1.3 Use of mistletoe ······	46
		1.3.1.3.1 Mistletoe therapy ·····	47
		1.3.1.3.2 Safety and efficacy	48
	1.3.2	Immunomodulation by mistletoe	49
	1.	3.2.1 Preclinical studies	49
	1.	3.2.2 Clinical studies ······	50
	1.3.3	γδ T cell immune responses to mistletoe·····	51
2.	Obj	ectives ·····	52
2	Mat	orials and Mothods	54
0.			54 54
	5.1	Antibodies	54
	3.2	Reagents ·····	55
	3.2.1	Complete medium	55
	3.2.2	Other reagents	55
	3.3	Sample collection ·····	55
	3.3.1	Ethics statement	55
	3.3.2	Samples of the Toxo project	56
	3.3.3	Samples of the Mistletoe project	56
	3.4	Flow cytometry	57
	3.4.1	FACS lysed samples ·····	57
	3.4.2	PBMC samples ·····	57
	3.4.3	Analysis ·····	58
	3.5	Cell culture and treatment ······	58
	3.5.1	Cell culture	58
	3.5.2	CD69 test ·····	58
	3.5.3	Proliferation test (including CFSE test) ······	58
	3.5.4	Cytokine test ·····	59
	3.5.5	CD107a test ·····	59
	3.5.6	Mevastatin test	59
	3.5.7	Apyrase treatment ·····	59
	3.5.8	BTN3 blocking test	59
	3.5.9	Heat treatment for mistletoe extracts	60
	3.5.1	0 Cell expansions	60
	3.6	Cell sorting ·····	60
	3.7	RNA isolation and CDR3 analysis	61
;	3.8	Dimensionality reduction and clustering	62
	3.9	Statistics ·····	62
4	Res	ults	64
		$\lambda_{\rm M}$	• <del>•</del>
,	4.1 	vyavoz i cells provide immunity to <i>i oxoplasma gondii</i> intection in the fetu	15 64
	1 2	Mistlatoo ovtract drugs stimulato anti cancor \/v0\/52 T colla	00
,	<b>T.</b>	misteree-extract arays sumulate and-cancer \$73002 1 Cells	33

5.	Ľ	Discussion ······121
	5.1	Vγ9Vδ2 T cells – born to work?······ 121
	5.2	Vγ9Vδ2 T cells and <i>T. gondii</i> – evolutionary rivals?······
	5.3	Vγ9Vδ2 T cells in mistletoe therapy – new target? ······· 126
	5.4	Vγ9Vδ2 T cells 'in practice'······128
6.	C	Conclusions and Perspectives······131
7.	F	References ······134
8.	A	Annex170